Insight Molecular Diagnostics

OCX · NASDAQ

$3.03+$0.14 (+4.84%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $2.89

Latest news

Press releaseMay 18, 9:02 AM ETPRNewswire
InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors
Press releaseJun 17, 7:00 AM ETGlobe Newswire
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
Press releaseMay 19, 4:05 PM ETGlobe Newswire
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Oncocyte Reports Q1 2025 Results and Business Progress
NewsMay 12, 4:32 AM ET
Earnings Scheduled For May 12, 2025
Press releaseMay 7, 4:10 PM ETGlobe Newswire
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Press releaseApr 30, 8:30 AM ETGlobe Newswire
Oncocyte Provides Positive Update on Clinical Trial Progress
Press releaseApr 29, 8:30 AM ETGlobe Newswire
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
Press releaseApr 24, 5:00 PM ETBusiness Wire
STAAR Surgical Announces Changes to Board of Directors
Press releaseApr 2, 8:45 AM ETGlobe Newswire
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
NewsApr 1, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 26, 8:11 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseMar 24, 4:05 PM ETGlobe Newswire
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
NewsMar 24, 4:32 AM ET
Earnings Scheduled For March 24, 2025
Press releaseMar 18, 4:05 PM ETGlobe Newswire
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Press releaseFeb 20, 4:02 PM ETBusiness Wire
Veradigm Announces Board Expansion and Changes
Press releaseJan 8, 8:30 AM ETGlobe Newswire
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Press releaseJan 6, 4:05 PM ETGlobe Newswire
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
Press releaseDec 4, 4:15 PM ETGlobe Newswire
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
NewsNov 12, 3:32 AM ET
Earnings Scheduled For November 12, 2024
NewsNov 11, 1:02 PM ET
What to Expect from OncoCyte's Earnings
Press releaseAug 20, 9:00 AM ETGlobe Newswire
PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
Press releaseAug 8, 4:05 PM ETGlobe Newswire
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

Oncocyte Reports Q1 2025 Results and Business Progress

Earnings Scheduled For May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

STAAR Surgical Announces Changes to Board of Directors

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Earnings Scheduled For March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Veradigm Announces Board Expansion and Changes

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Earnings Scheduled For November 12, 2024

What to Expect from OncoCyte's Earnings

PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results